Metabolic control results from meta-analysis of studies comparing short-acting insulin analogues with human regular insulin in patients with type 1 or type 2 diabetes mellitus (DM)
| Patients | ||
|---|---|---|
| Type 1 DM | Type 2 DM | |
| HbA1c | ||
| No. studies | 22 | 5 |
| WMD (95% CI) | −0.1%a (−0.2 to −0.1) | 0.0% (−0.1 to 0.0) |
| Continuous SC injection subgroup (7 studies) | −0.2%a (−0.3 to −0.1) | — — |
| Multiple dose injections subgroup (15 studies) | −0.1% (−0.1 to 0.0) | — — |
| Overall hypoglycemia | ||
| No. studies | 10 | 10 |
| WMD mean events/pt/mo (95% CI) | −0.2% (−1.1 to 0.7) | −0.2% (−0.5 to 0.1) |
| Severe hypoglycemia | ||
| No. studies, 28 | Not reported | Not reported |
| Median events/100 person-years, insulin analogue vs regular insulin | 21.8 vs 46.1 | 0.3 vs 1.4 |
↵a Statistically significant in favor of insulin analogues vs regular insulin.
CI = confidence interval; SC = subcutaneous; WMD = weighted mean difference.
Based on data in Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006; 19:CD003287.